Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics adds Kevin Tracey to board; lowers shareholder bylaw amendment vote to majority

Neutral Impact 3 of 5 leadership Written later

United Therapeutics appointed Kevin J. Tracey, M.D., to its Board of Directors on January 21, 2026, increasing the Board to 13 members. The Board also adopted an Eleventh Amended and Restated Bylaws, which lowers the shareholder vote needed to alter, repeal, or amend the bylaws from 80% to a majority of voting power and adds a cure process for certain director nomination notices.

Key points

  • Kevin J. Tracey, M.D., joined the Board on January 21, 2026; he will not serve on a Board committee initially.
  • Board size increased to 13 members; Dr. Tracey received 1,220 restricted stock units on January 21, 2026.
  • Shareholder vote needed to amend the bylaws drops from 80% to a majority of voting power of outstanding shares entitled to vote generally in director elections.
  • Bylaws now allow shareholders to cure certain deficiencies in director nomination notices within the specified time period.

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECJan 22, 2026, 4:31 PM ET
Accession number0001104659-26-005810

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.